Jan 30, 2026
Which diseases are currently treated or targeted by karylef clinical trials?
’s clinical programs, centered on the selective inhibitor of nuclear export selinexor (XPOVIO) and related agents, are targeting a spectrum of hematologic malignancies and solid tumors—most prominentl...